SGLT2 Inhibitors Before Surgery: Time to Rethink?
About this episode
This episode discusses the implications of a new consensus on SGLT2 inhibitors before surgery and the potential benefits of continuing therapy for certain patients.
Should every patient stop their SGLT2 inhibitor before surgery? A new consensus published in the British Journal of Anaesthesia challenges the long-standing FDA recommendation of a universal 3–4 day hold. In this episode, we unpack the evidence, discuss which patients may actual ly benefit from continuing therapy, and explain how to balance the risk of euglycemic diabetic ketoacidosis against the cardiovascular and renal protection these drugs provide. Read more about this topic HERE . ====================================== Where else to find us: Web - https://www.nysora.com/ Instagram - instagram.com/nysora.inc/ LinkedIn - linkedin.com/company/nysora-inc/ Facebook - facebook.com/nysora Twitter - x.com/nysora TikTok - tiktok.com/@nysora_inc --------------------------------------------------------- #nysora #regionalanesthesia #anesthesia Disclaimer: Medicine is an ever-changing science. As new research and clinical…
Topics covered
- SGLT2 inhibitors
- surgery
- diabetes management
- cardiovascular protection
- renal protection
Keywords
- SGLT2 inhibitors
- surgery
- diabetic ketoacidosis
- cardiovascular protection
- renal protection
Mentioned in this episode
Organizations: British Journal of Anaesthesia, FDA
Products: SGLT2 inhibitor
More episodes of Anesthesia Updates
- Frailty or Age?
- AI and Anesthesia Education
- Rethinking Diabetes Meds in the OR
- Pediatric Regional Anesthesia: What the Evidence Actually Says
Explore listener stats, chart rankings, contacts and more on the Anesthesia Updates podcast page.